Join the Rybelsus group to help and get support from people like you.
Rybelsus News (Page 7)
Semaglutide Does Not Increase Psychiatric Complications in Overweight, Obesity
TUESDAY, Sept. 3, 2024 – Treatment with semaglutide does not increase the risk for developing symptoms of depression or suicidal ideation/behavior among adults with overweight or obesity, according...
Semaglutide Reduces Risk for MACE in Patients With Obesity and Heart Failure
WEDNESDAY, Aug. 28, 2024 – Semaglutide reduces the risk for major adverse cardiovascular events (MACE) and composite heart failure end points compared with placebo in patients with overweight or...
After Weighting, 3.6 Million Likely to Be Newly Eligible for Semaglutide
MONDAY, Aug. 26, 2024 – Increases in eligibility for semaglutide are discussed in a research letter published online Aug. 27 in the Annals of Internal Medicine. After the Semaglutide Effects on...
Semaglutide-Linked Suicidal Ideation ID'd in Disproportionality Analysis
WEDNESDAY, Aug. 21, 2024 – Semaglutide-associated suicidal ideation has been identified in a disproportionality analysis, according to a study published online Aug. 20 in JAMA Network Open. Georgios...
GLP-1 RA Use Linked to Lower Rates of Hyperkalemia in Type 2 Diabetes
MONDAY, Aug. 12, 2024 – Treatment with glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and a lower rate of renin-angiotensin system inhibitor...
Cost Keeps Many Who Need Them From Getting New Weight-Loss Meds
WEDNESDAY, Aug. 7, 2024 (HealthDay news) – Medicare and Medicaid patients are less likely to get cutting-edge weight-loss drugs than people with private insurance are, a new study finds. Medicaid...
2021 to 2023 Saw Considerable Increase in Semaglutide Fills
MONDAY, Aug. 5, 2024 – From 2021 through 2023, there was a considerable increase in the number of semaglutide fills, according to a research letter published online Aug. 2 in JAMA Health Forum....
FDA Medwatch Alert: Drug Safety Communication: Certain Type of Medicines Approved for Type 2 Diabetes and Obesity - Update on FDA’s Ongoing Evaluation of Reports of Suicidal Thoughts or Actions
ISSUE: The FDA has been evaluating reports of suicidal thoughts or actions in patients treated with a class of medicines called glucagon-like peptide-1 receptor agonists (GLP-1 RAs; see the list in...
FDA Medwatch Alert: FDA Issues Warning About Compounded Medications Containing Semaglutide Marketed for Type 2 Diabetes or Weight Loss
On May 30, 2023, the FDA posted information about medications containing semaglutide marketed for type 2 diabetes or weight loss. There are currently three FDA-approved semaglutide products which are...
Novo Nordisk Announces FDA Approval of Label Update for Rybelsus (semaglutide) Allowing Use as a First-Line Option for Adults with Type 2 Diabetes
People living with type 2 diabetes can now take Rybelsus®, the first and only oral glucagon-like peptide-1 (GLP-1) analog, along with diet and exercise, as initial therapy to help lower their A1C1,2 ...
FDA Approves Rybelsus (semaglutide), the First Oral GLP-1 Analog Treatment for Adults with Type 2 Diabetes
PLAINSBORO, N.J., Sept. 20, 2019 /PRNewswire/ – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Rybelsus (semaglutide) tablets 7 mg or 14 mg for adults...